POPs Regulation Update: HealthTech Exemption Safeguards Patient Access
This week, a third Statutory Instrument (SI) came into effect which omits HealthTech from the UV-328 and Dechlorane Plus entries in the UK's Persistent Organic Pollutants (POPs) legislation. This means that, for the time being, the restriction on these two substances has been lifted for our sector. The SI's accompanying Impact Assessment provides detailed background on the decision.
Over the past year, we have engaged extensively with the Department for Health and Social Care (DHSC), the Department for Environment, Food and Rural Affairs (Defra), and members, to understand and communicate the real-world impact this legislation would have had. Just one member estimated that the restrictions could have affected tens of thousands of patients they serve. Without an exemption, essential technologies could have been withdrawn, risking significant disruption to care.
This is a powerful example of the role we play in advocating for our sector, ensuring that policy, however well-meaning, does not unintentionally jeopardise patient access to critical products. I am grateful to our members for their input into this work, as it is only with your evidence and insight that we can make a compelling case to government. This outcome would not have been possible without your engagement.
Defra have stated their intention to consider restrictions at a later date, allowing time for industry to identify suitable chemical alternatives and apply for relevant exemptions. It should also be recognised that UV-328 and Dechlorane Plus are just two of the substances listed under the Stockholm Convention, so it remains important to map where these may be present across your supply chains.
Please, therefore, continue to share how environmental legislation is impacting your business. As we collectively support sustainability efforts, we must also ensure that regulatory approaches protect the continued supply of safe, effective technologies for patients.
